CD274 and cancer: Targeting SHP2, a protein tyrosine phosphatase, by PROTACs is useful for cancer immunotherapy partly via regulation of several signaling pathways, such as PD-1/PD-L1, PI3K/AKT, RAS/ERK, JAK/STAT pathways (99).